Mingchen Yan

Dr. Mingchen Yan

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2020 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
JSJing Sun
Jing Sun
YZYanfang Zhang
Yanfang Zhang
MWMinhui Wang
Minhui Wang
QGQian Guan
Qian Guan
XYXiujia Yang
Xiujia Yang
ZZZhenhai Zhang
Zhenhai Zhang
Identification of genetic variants via high-throughput sequencing (HTS) technologies has been essential for both fundamental and clinical studies. However, to what extent the genome sequence composition affects variant calling remains unclear. In this study, we identified 63,897 multi-copy sequences (MCSs) with a minimum length of 300 bp, each of which occurs at least twice in the human genome. The 151,749 genomic loci (multi-copy regions, or MCRs) harboring these MCSs account for 1.98% of the genome and are distributed unevenly across chromosomes. MCRs containing the same MCS tend to be located on the same chromosome. Gene Ontology (GO) analyses revealed that 3800 genes whose UTRs or exons overlap with MCRs are enriched for Golgi-related cellular component terms and various enzymatic activities in the GO biological function category. MCRs are also enriched for loci that are sensitive to neocarzinostatin-induced double-strand breaks. Moreover, genetic variants discovered by genome-wide association studies and recorded in dbSNP are significantly underrepresented in MCRs. Using simulated HTS datasets, we show that false variant discovery rates are significantly higher in MCRs than in other genomic regions. These results suggest that extra caution must be taken when identifying genetic variants in the MCRs via HTS technologies.

26 February 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
BLBinghang Liu
Binghang Liu
MBMuqun Bai
Muqun Bai
FZFei Zheng
Fei Zheng
MYMingchen Yan
Mingchen Yan
EHEnen Huang
Enen Huang
JWJun Wang
Jun Wang
Background/Objectives: The development of vaccines that elicit both T-cell and B-cell responses is crucial for effective immunity against pathogens. This study introduces a novel approach to identify precise epitope peptides within viral proteins that can stimulate both arms of the adaptive immune response, using Porcine Parvovirus (PPV) as a model. Methods: Mice were infected with PPV, and a peptide array was utilized to detect IgG signals in their sera. This approach facilitated the assessment of the immunogenicity of the PPV proteome, leading to the identification of 14 potential epitope candidates. These candidates were then used to immunize additional mice, and their ability to induce T-cell and B-cell responses was evaluated. Results: The immunization experiments identified an optimal peptide, P6, which robustly activated both T cells and B cells. Further analysis of the sub-regions of this peptide confirmed P6 as the most potent inducer of immune responses. The anticipated epitope was detected in mice immunized with P6, highlighting the efficacy of our method in identifying epitopes that engage both T cells and B cells. Conclusions: This study presents a novel strategy for the identification of dual T-cell and B-cell epitopes by directly evaluating the immunoreactivity of antibodies in serum. This finding holds significant promise for the advancement of epitope-based vaccines.

19 February 2026 in Biology
Verified
Journal Article
Open access
PDF file
LYLifang Yuan
Lifang Yuan
ZOZhiyao Ouyang
Zhiyao Ouyang
YZYifan Zhao
Yifan Zhao
RBRongjun Bi
Rongjun Bi
YWYanjing Wu
Yanjing Wu
YCYongkun Chen
Yongkun Chen
Influenza’s pandemic threat is driven by antigenic drift, which limits the efficacy of conventional vaccines. To address this challenge, we established a clinical serum-anchored computational design pipeline for a broad-spectrum multi-epitope mRNA vaccine (MEMV), bridging the gap between pure in silico design and clinical applicability. Using 36 longitudinal sera (d0/d28/d365) from 12 well-characterized human cohorts (6 vaccine recipients and 6 influenza patients) and high-density antibody-peptide microarrays, we empirically identified 12 immunodominant B-cell linear epitopes from the nucleoprotein (NP) of influenza A (H1N1/H3N2) and B viruses. These experimentally validated epitopes were combined with in silico-predicted conserved helper T-lymphocyte (HTL)/cytotoxic T-lymphocyte (CTL) epitopes (from NP/HA/NA) to construct MEMVs candidates, ensuring high antigenicity, non-toxicity, and 95.63% global HLA coverage. Molecular docking and 100 ns molecular dynamics (MD) simulations confirmed favorable conformational compatibility between MEMVs and Toll-like receptor 3 (TLR3) in silico immunization via C-ImmSim predicted robust B/T-cell responses and protective cytokine (IFN-γ/IL-10) production. Collectively, this pipeline shortens the preliminary design cycle for influenza vaccines, provides a standard epitope-combination strategy, and offers direct targets for follow-up in vitro/in vivo experiments.

17 February 2026 in Journal of Computational Biophysics and Chemistry
Verified
Journal Article
Closed access
STShuaizhen Tian
Shuaizhen Tian
XDXinxin Du
Xinxin Du
MLMingli Li
Mingli Li
MYMingchen Yan
Mingchen Yan
TZTong Zhu
Tong Zhu
John ZhangJohn Zhang
John Zhang